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Abstract 161 
Background 162 
Cytotoxic-T-lymphocyte-antigen-4 (CTLA-4) is a negative immune regulator. Heterozygous CTLA4 163 
germline mutations can cause a complex immune dysregulation syndrome in humans.  164 
Objective  165 
To characterize the penetrance, the clinical features and the best treatment options in 133 CTLA4 166 
mutation carriers. 167 
Methods 168 
Genetics, clinical features, laboratory values, and outcome of treatment options were assessed in a 169 
worldwide cohort of CTLA4 mutation carriers.  170 
Results 171 
We identified 133 individuals from 54 unrelated families carrying 45 different 172 
heterozygous CTLA4 mutations, including 28 previously undescribed mutations. Ninety mutation 173 
carriers were considered affected, suggesting the clinical penetrance of at least 67%; median age of 174 
onset was 11 years, and mortality rate within affected mutation carriers was 16% (n=15).  175 
Main clinical manifestations included hypogammaglobulinemia (84%), lymphoproliferation (73%), 176 
autoimmune cytopenia (62%), respiratory- (68%), gastrointestinal- (59%), or neurological features 177 
(29%). Eight affected mutation carriers developed lymphoma, three gastric cancer. An EBV 178 
association was found in six malignancies. CTLA4 mutations were associated with lymphopenia and 179 
decreased T-, B-, and NK-cell counts. Successful targeted therapies included the application of CTLA-180 
4-fusion-proteins, mTOR-inhibitors, and hematopoietic stem cell transplantation. EBV reactivation 181 
occurred in two affected mutation carriers under immunosuppression. 182 
Conclusions 183 
Affected mutation carriers with CTLA-4 insufficiency may present in any medical specialty.  Family 184 
members should be counseled, as disease manifestation may occur as late as age 50. EBV- and CMV-185 
associated complications must be closely monitored. Treatment interventions should be coordinated 186 
in clinical trials.  187 
 8 
Clinical Implication 188 
This large cohort of affected CTLA4 mutation carriers gives first insights into different possible 189 
treatment options and presents available clinical information on treatment response and survival. 190 
With this knowledge, affected mutation carriers will benefit from an individualized management. 191 
 192 
Capsule summary 193 
We present the clinical spectrum, new mutations, and possible modifiers of the world-wide largest 194 
cohort of CTLA4 mutation carriers. We encourage physicians to consider mutations in genes such as 195 
CTLA4 as a monogenetic cause for complex disease presentations.  196 
 197 
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Introduction 214 
Heterozygous germline mutations in cytotoxic T lymphocyte antigen 4 (CTLA4) can lead to 215 
haploinsufficiency, impaired CTLA-4 dimerization, or impaired ligand binding, and can cause an 216 
autosomal dominant immune dysregulation syndrome and immunodeficiency in humans.(1-3) CTLA-217 
4 is a negative immune regulator essential for the function of regulatory T cells (Tregs), which are 218 
responsible for maintaining self-tolerance and immune homeostasis through the suppression of T cell 219 
proliferation and differentiation.(4-9) CTLA-4 competes with the costimulatory receptor CD28 for its 220 
ligands CD80 and CD86, expressed on antigen-presenting cells (APCs).(10, 11) CTLA-4 binds these 221 
ligands with a higher affinity and avidity than CD28 and removes them from the surface of APCs via 222 
transendocytosis, resulting in a reduction of APC-mediated activation of conventional T cells.(12, 13) 223 
CTLA4 encodes for four exons; exon 1 encodes the signal peptide, exon 2 the ligand binding and 224 
dimerization domains, exon 3 the transmembrane domain, and exon 4 the cytoplasmic tail.(14) 225 
The clinical diagnosis of CTLA-4 insufficiency is complicated by a highly variable phenotype including 226 
various organ-specific autoimmune diseases, hypogammaglobulinemia, recurrent infections, and 227 
malignancies; the natural history of this condition is largely unknown.(1, 3, 15-19) CTLA-4 228 
insufficiency in humans was associated with incomplete penetrance.  229 
Here, we describe the largest known cohort of CTLA4 mutation carriers including 133 individuals to 230 
aid diagnosis in similar cases and give guidance for their treatment.  231 
 232 
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Methods 241 
See Supplements.  242 
 243 
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Results 268 
 269 
Age distribution and origin 270 
We identified 133 individuals of 54 unrelated families (66 female, 67 male) from Europe (n=87), Asia 271 
(n=26), South America (n=7), and North America (n=13) (Table 1, Figure 1). Median age of onset was 272 
11 (<1 to 59) years, median age at evaluation was 23 years in affected mutation carriers, and 46 273 
years in unaffected carriers (Figure 2). Three-fourths of affected mutation carriers were under the 274 
age of 18 years when showing first symptoms; there was no significant difference in the age of onset 275 
between women and men.  276 
 277 
Genetics and protein function 278 
We identified 45 unique heterozygous CTLA4 germline mutations including 28 missense mutations, 279 
ten deletions or insertions, and seven nonsense mutations (Table 1, Figure 3). Mutations in seven 280 
affected carriers had occurred de novo. Twenty-eight mutations were novel and seventeen have 281 
previously been described.(1, 3, 15, 17-21) Eight mutations were located in exon 1, 31 in exon 2 and 282 
six within exon 3. Mutations at seven loci were identified in multiple families (Table 2). CTLA-4 283 
expression within stimulated Tregs was reduced in all tested CTLA4 mutation carriers. CD4+ T cells 284 
were co-cultured with CD80-GFP-expressing CHO cells and GFP-uptake was measured within CTLA-4 285 
positive cells to estimate the ability of cells to perform transendocytosis, which was reduced in all 286 
tested mutation carriers (Table 1, Figure S1).(13) An association between genotype and onset, 287 
penetrance, or disease phenotype was not observed. So far 115 exonic variants have been described 288 
within CTLA4; all but two variants have a minor allele frequency (MAF) <0.01, seven variants have 289 
been described to be disease causing or are part of our cohort (Table S3). (1, 2, 19) 290 
 291 
Symptoms and signs at presentation  292 
First symptoms included autoimmune cytopenia (33%), respiratory manifestations (21%), 293 
enteropathy (17%), type 1 diabetes (8%), neurological symptoms (seizures, headache, nausea) (6%), 294 
 12 
thyroid disease (5%), arthritis (3%), growth retardation, fever or night sweats, atopic dermatitis, 295 
alopecia (2% each), and primary biliary cirrhosis, Addison’s disease, or a wound healing disorder, in 296 
one affected mutation carrier each. 297 
 298 
Main diagnoses  299 
At the time of data collection, affected mutation carriers had diverse main diagnoses: Twenty-six 300 
(29%) had a diagnosis of cytopenia and 23 (26%) had common variable immunodeficiency (CVID). 301 
CVID was diagnosed according to the revised European society of immune deficiencies (ESID) 302 
registry.(22) Twenty affected mutation carrier (22%) suffered mainly from severe gastrointestinal 303 
symptoms such as enteropathy or inflammatory bowel disease (IBD) and ten (11%) from respiratory 304 
disease including infections (n=9), granulomatous lymphoproliferative interstitial lung disease (GLILD, 305 
n=9), bronchiectasis (n=9), and asthma (n=2). In seven affected mutation carriers (8%) lymphoma 306 
was the leading diagnosis, five (6%) had mainly endocrinopathies, and four (4%) had inflammatory 307 
CNS disease. Individual affected mutation carriers had widespread lymphadenopathy (n=3, 3%), an 308 
autoimmune lymphoproliferative syndrome (ALPS)-like phenotype (n=2, 2%), an immune 309 
dysregulation polyendocrinopathy enteropathy X-linked syndrome (IPEX)-like phenotype (n=1, 1%), a 310 
primary biliary cirrhosis (n=1, 1%), liver cirrhosis of unknown etiology (n=1, 1%), rheumatoid arthritis 311 
(n=1, 1%), and psoriatic arthritis (n=1, 1%). Ten affected mutation carriers (11%) had several main 312 
diagnoses (Table S1). At the time of data collection 65 affected mutation carriers were under 313 
immunosuppression. Forty-three mutation carriers were considered unaffected (Table S1).  314 
 315 
Clinical spectrum of CTLA-4 insufficiency 316 
While CTLA4 mutations were associated with autoimmunity and immune dysregulation in all affected 317 
mutation carriers, the affected organ systems varied substantially: hypogammaglobulinemia (84%), 318 
lymphoproliferation (73%), respiratory involvement (68%), gastrointestinal features (59%), 319 
autoimmune cytopenia (62%), dermatological involvement (56%, mainly atopic dermatitis), 320 
endocrinopathy (33%), and neurological features (29%) were often observed. Arthritis (14%), growth 321 
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retardation (14%), renal (12%) or liver (12%) involvement were less frequent (Figure 4, Table S1). One 322 
affected mutation carrier had severe psoriatic arthritis (T.II.1). In total, ninety of the 133 CTLA4 323 
mutation carriers (67.6%) were considered affected, as they had sought medical attention for 324 
disease-related symptoms. Case reports can be found in the Supplements.  325 
 326 
Non-malignant lymphoproliferation  327 
Sixty-two affected mutation carriers (73%) had non-malignant lymphoproliferation, including 328 
splenomegaly (n=51, Figure 3, Figure 5 Panel A), chronic lymphadenopathy (n=43), and 329 
hepatomegaly (n=17). Thirteen affected mutation carriers underwent splenectomy for severe 330 
cytopenia. Forty-three affected mutation carriers (50%) had lymphocytic infiltrations into lung 331 
(n=27), gastrointestinal tract (n=17), brain (n=12), bone marrow (n=6, Figure 6 Panel E), kidney (n=6), 332 
or retroperitoneal tissue (n=4). Upon biopsy, 21 affected mutation carriers had T cell infiltrations, 333 
both CD4+ (n=9) and CD8+ (n=8) infiltrations were observed. Twelve predominately had B cell 334 
infiltrations, four of them in the lung tissue as part of their GLILD. Ten out of 29 biopsied affected 335 
mutation carriers with non-malignant lymphoproliferation also had granulomas in at least two 336 
different organ systems upon biopsy; eight in the lung, two in the lymph nodes, and one each in 337 
kidney, brain, or gastrointestinal tract. 338 
 339 
Respiratory tract involvement 340 
Respiratory tract involvement was common (68%; 61/90; Figure 5 Panels C, D, E; Figure 6 Panel A, B) 341 
including recurrent lower (n=48) and upper (n=41) respiratory tract infections, granulomatous-342 
lymphocytic interstitial lung disease (GLILD) (n=32), and bronchiectasis (n=20). Two affected 343 
mutation carriers underwent lung transplantation due to idiopathic lung fibrosis (B.III.2) or common 344 
variable immunodeficiency (CVID) (23) with recurrent infections, emphysema, and parenchymal lung 345 
damage (A.II.9); both died 12 and 15 months, respectively, after transplantation due to pulmonary 346 
demise following a relapse of disease.  347 
 348 
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Pathogens and infections  349 
Sixty-one percent of affected mutation carriers (55/90) had respiratory tract infections including 350 
pneumonia, sinusitis, and otitis media. Isolated pathogens were Haemophilus influenzae (n=6) and 351 
Streptococcus pneumoniae (n=4). The most common enteritis pathogen was Salmonella enteritidis 352 
(6/7). Staphylococcus aureus was detected in various organs of eleven affected mutation carriers. 353 
Twenty-seven affected mutation carriers reactivated a Herpes virus infection: Epstein-Barr virus 354 
(EBV) led to clinically apparent infections in sixteen affected mutation carriers (Figure 6 Panel C), 355 
including EBV-induced hemophagocytic lymphohistiocytosis (B.II.3). Two affected mutation carriers 356 
developed EBV-associated lymphoid granulomatosis in lung or brain (H.II.2, N.III.2). Cytomegalovirus 357 
(CMV) reactivation was found in nine affected mutation carriers including CMV-associated diarrhea 358 
or gastritis (D.II.1, M.II.3, NN.II.1), chronic active CMV infection (LL.II.1), CMV lymphadenitis (K.II.1), 359 
bilateral parotid hypertrophy (O.II.1), and respiratory CMV infection (R.II.5); eight of them were on 360 
immunosuppressive treatment. Mycobacterium tuberculosis polymerase chain reaction was positive 361 
in four affected mutation carriers, with two of them developing pulmonary or esophageal 362 
tuberculosis (A.II.8, A.II.9).  363 
Fungal infections were present in 15 affected mutation carriers with either Candida species pluralis 364 
infections (n=13) or Aspergillus species pluralis pneumonia (n=2); thirteen of them received 365 
immunosuppressive treatment at the time of data collection. Ten affected mutation carriers, of 366 
whom eight were immunosuppressed, developed sepsis due to bacterial or fungal pathogens leading 367 
to death in five. In one affected mutation carrier sepsis followed a perforation of the small bowel, 368 
and in one Salmonella enteritidis sepsis was the first manifestation of CTLA-4 insufficiency at the age 369 
of three months (UU.IV.12).  370 
 371 
Gastrointestinal involvement 372 
Gastrointestinal involvement across our cohort was frequent (59%; 53/90) and often severe. Nine of 373 
the 15 deceased affected mutation carriers had severe gastrointestinal features prior to their death. 374 
Diarrhea was frequent (n=51), ranging from mild to severe diarrhea with weight loss, wasting, and 375 
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total parenteral nutrition-dependency. Pathogens were rarely identified. Crohn disease (n=7), 376 
atrophic gastritis (n=8) (Figure 6 Panel D), coeliac disease (JJ.II.1), acute pancreatitis (M.II.3), and 377 
pancreatic insufficiency (N.III.2, QQ.II.1) were observed. In three affected mutation carriers, severe 378 
long-lasting CVID-gastroenteropathy preceded gastric cancer (B.II.4, G.III.2, M.II.3). Macroscopic 379 
findings ranged from normal appearing mucosa albeit histologically proven deep T cell infiltrations in 380 
the submucosa, to superficial ulcerative lesions or deep-seated inflammatory changes as seen in 381 
severe Crohn’s disease. Despite decreased serum immunoglobulin levels, histology revealed 382 
increased numbers of plasma cells in the gastric (B.II.4, QQ.II.1), intestinal, and colonic (QQ.II.1) 383 
lamina propria. Further histology changes included severe lymphocytic infiltrates, and EBV-positive 384 
gastric cancer (Figure 6 Panel C).  Median age of onset of gastrointestinal features was 15 (<1 to 51) 385 
years.  386 
 387 
Cytopenia 388 
Autoimmune cytopenia was often severe, life-threatening, and treatment-resistant and formed the 389 
main indication for allogeneic hematopoietic stem cell transplantation (alloHSCT) (7/12).  390 
Sixty-two percent of affected mutation carriers (55/89) had autoimmune cytopenia, including 391 
immune thrombocytopenia (n=41), autoimmune hemolytic anemia (n=37), pure red cell aplasia 392 
(PRCA) (n=2) or autoimmune neutropenia (n=16). In 32 affected mutation carriers cytopenia affected 393 
more than one cell lineage, nineteen of those were diagnosed with Evans syndrome, and nine had a 394 
trilineage cytopenia. Median age of onset of cytopenia was 12 (1.3 to 48) years.  395 
 396 
Neurological involvement   397 
Twenty-eight percent of affected mutation carriers (28/90) presented with a broad spectrum of 398 
neurological features (Figure 5 Panel F, G, H, Figure 6 Panel F). Three had autoimmune encephalitis 399 
or encephalomyelitis with cerebral perivascular lymphocytic infiltrations leading to vomiting, 400 
headache or paraplegia with bladder dysfunction (N.III.2, P.II.2, GG.II.1). In four affected mutation 401 
carriers neurological features were attributed to cerebral infiltrations that were not biopsied: nausea 402 
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and headache (A.III.1), facial nerve paralysis (H.II.1), aphasia and paresis of the left arm (K.II.1), or a 403 
patchy inflammatory demyelinating process with twitching episodes of hands with normal 404 
electroencephalography (WW.II.1). Three affected mutation carriers had neurological features 405 
secondary to hematological causes: hemiplegia following brain ischemia during AIHA (DD.II.1), 406 
hemiparesis and aphasia due to cerebral arterial thrombosis (H.II.2), hemiparesis following cerebral 407 
bleeding due to thrombocytopenia (GG.II.1). In two affected mutation carriers clinical and 408 
radiological investigation could not identify an underlying cause for tonic-clonic seizures, or recurrent 409 
transient paralysis of the left leg respectively (A.II.8, EE.II.1).  One affected mutation carrier had life-410 
threatening HLH with increased cerebral pressure leading to cerebral herniation and seizures (J.II.1). 411 
Other diagnoses were stiff person syndrome (H.I.2), West-syndrome and developmental delay 412 
(UU.V.1), progressive memory loss starting age 57 years (UU.III.7), and chronic hydrocephalus 413 
(UU.III.4). Two affected mutation carriers suffered from optic neuritis (TT.II.4) and retinal tear due to 414 
lymphocytic infiltrations into the retina (SS.II.1). One had gliosis (ZZ.II.1) and one developed cognitive 415 
dysfunction, chorea, ataxia, and mood instability; biopsies revealed inflammation, lymphocytic 416 
infiltrations, and a demyelinating-like transformation, which was clinically responsive to steroid 417 
treatment (G.III.1). One affected mutation carrier was diagnosed with tuberous sclerosis with tonic-418 
clonic seizures, right-sided hemiparesis, mental retardation, angiofibromas, angiomyolipomas, and a 419 
concurrent TSCA2 mutation (LL.II.1).  420 
 421 
Malignancies  422 
Eleven affected mutation carriers (12%) developed malignancies. Out of eight with lymphoma, EBV-423 
positivity was found in five. Lymphoma in five affected mutation carriers was classified as Hodgkin 424 
lymphoma; one developed a relapsing EBV-associated diffuse large B cell lymphoma (K.II.1) and one a 425 
Burkitt lymphoma (FF.II.1) (Figure 6 Panel G, H). Four affected mutation carriers died due to 426 
complications of their lymphoma, two underwent successful alloHSCT.  427 
Three affected mutation carriers developed a gastric adenocarcinoma, including one EBV-associated 428 
carcinoma (B.II.4, Figure 6 Panel C), and one CMV-associated carcinoma (M.II.3). Two affected 429 
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mutation carriers subsequently underwent total gastrectomy, one of whom died following bacterial 430 
sepsis (M.II.3) while the other one is alive and well (G.III.2).  431 
 432 
Fatal Outcome  433 
Sixteen percent of affected mutation carriers (15/90) died due to their clinical manifestations or 434 
resulting complications at a median age of 23 (14 to 60) years. Four died of sepsis on a background of 435 
wasting enteropathy, Evans syndrome, or CVID with infections (M.II.3, G.III.1, C.II.3, L.I.2). Three died 436 
due to complications of Non-Hodgkin lymphoma (K.II.1, FF.II.1, UU.III.3), one died during 437 
chemotherapy of his Hodgkin lymphoma due to septic multi-organ failure (H.II.1), and two following 438 
lung transplantation and relapse of disease (A.II.9, B.III.2). One affected mutation carrier died of 439 
acute liver failure following many years of gastrointestinal disease (B.II.2). Wasting enteropathy, 440 
respiratory insufficiency, and neurological features led to death in one affected mutation carrier 441 
(A.II.8). Another one suffered from severe enteropathy and cytopenia, and died following colectomy 442 
(F.II.1). Three affected mutation carriers died following alloHSCT due to GvHD (Q.II.1, LL.II.1) or due 443 
to diabetic ketoacidosis (S.II.1). There was a significant difference of the age of death between 444 
affected and the unaffected CTLA4 mutation carriers (Figure 2 B).  445 
 446 
Immunological phenotype  447 
Thirty-nine percent (26/66) of affected mutation carriers with available immunological data had 448 
lymphopenia of which twenty-four were under immunosuppressive treatment at the time of data 449 
collection. The absolute CD3+ T cell count was reduced in 36% (16/44) of affected mutation carriers. 450 
The absolute CD3+CD4+ helper T cell count was reduced in 20% (13/62) of affected mutation carriers 451 
especially due to the noteworthy reduction of naïve CD4+ T cells. An elevated percentage of the 452 
activation marker HLA-DR+ was seen in one third of tested affected mutation carriers (11/31). 453 
Percentage of CD4+FoxP3+ Tregs was significantly increased in mutation carriers in comparison to 454 
healthy controls (p=0.0034). There was no significant difference in the Treg percentage between 455 
affected and unaffected mutation carriers (p=0.3882). Eight mutation carriers had Treg numbers 456 
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above the normal range. Absolute CD3+CD8+ cytotoxic T cell count was normal in 60% (35/58) of 457 
affected mutation carriers. Double-negative T cells were elevated up to 5.3% (median 2.2%; norm: 458 
0.3-2.0%) in 53% of tested affected mutation carriers (9/17). Absolute CD19+ B cell counts were 459 
reduced in 41% (26/58) of affected mutation carriers. B cell subsets showed a decrease in switched 460 
memory B cells (23/30) and consecutively a relative increase in naïve B cells (14/29). CD21-low B cells 461 
were elevated in all affected mutation carriers tested. Five affected mutation carriers with no history 462 
of rituximab therapy had no measurable B cells. Hypogammaglobulinemia was present in 84% 463 
(65/77), with low IgM in 30, low IgG in 42, and low IgA in 53 affected mutation carriers (Figure 4). 464 
Absolute CD16+CD56+ NK cell counts were reduced in 52% (32/61). The percentage of CD3+ and 465 
CD3+CD4+ was increased in the majority of affected mutation carriers, as the overall lymphopenia 466 
affected CD3+CD8+, B, and NK cells more than the CD4 compartment (Figure S2). Antinuclear 467 
autoantibodies (ANA) and anti-neutrophil cytoplasmic antibodies (ANCA) were the most commonly 468 
measured autoantibodies; however, they were negative in most affected mutation carriers (ANA 469 
(4/51), ANCA (3/42)). 470 
 471 
Treatment  472 
CTLA-4 fusion proteins and mTOR inhibitors  473 
CTLA-4 replacement by CTLA-4-Fc, or inhibition of the CD28 signaling pathway through mTOR 474 
inhibitors are potential targeted therapies to inhibit the underlying hyper-active signaling in CTLA4 475 
mutation carriers.  476 
In total, fourteen affected mutation carriers received the CTLA-4 fusion proteins abatacept or 477 
belatacept; eleven of whom responded with an improvement of their clinical symptoms. In six of 478 
them enteropathy improved, leading to normal stool frequency and weight gain within three months 479 
(B.II.4, D.II.1, L.II.2, HH.II.1, SS.II.1, VV.II.1, Figure S3). In two affected mutation carriers primarily 480 
presenting with GLILD (RR.II.1, SS.II.1), CTLA4-Fc led to resolution of lymphoproliferation in the lung 481 
(SS.II.1), cough and sputum production decreased, and sIL2R concentration dropped from 1228 U/ml 482 
to 750 U/ml within five months (RR.II.1). Other observations were an improvement of 483 
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lymphadenopathy (G.III.2), stabilization of platelet counts, resolution of bleeding episodes, and 484 
regression of optic neuritis (TT.II.4). In two affected mutation carriers, additional systemic 485 
immunosuppressive medication could be reduced, as abatacept treatment led to inhibition of the 486 
disease progression (J.II.1) or to improvement of lung function and diarrhea (PP.II.1). In six affected 487 
mutation carriers treatment was discontinued: three underwent alloHSCT (L.II.2, VV.II.1, GG.II.1), two 488 
had an EBV reactivation (B.II.3, B.II.4), and one developed severe respiratory infections, neutropenia, 489 
and agranulocytosis (TT.II.4).  490 
Thirteen affected mutation carriers were treated with the mTOR inhibitor sirolimus with a good 491 
response in eight (D.II.1, E.II.3, L.II.2, O.II.1, P.II.2, Z.III.1, TT.II.5, WW.II.1). Improvement of clinical 492 
features included resolution of transfusion-dependent PRCA (Z.III.1), regression of lymphadenopathy 493 
and splenomegaly, reduced IG consumption, and improved CMV viral load (O.II.1). Enteropathy 494 
improved in three affected mutation carriers following combination of sirolimus with either 495 
prednisolone (D.II.1), belatacept (L.II.2), or rituximab and steroids (WW.II.1). In one affected 496 
mutation carrier cytopenia stabilized on co-medication with rituximab, but neurological features and 497 
severe aphthae occurred (P.II.2). Sirolimus led to reduced spleen size (volume decreased from 5l to 498 
2.8l) in one affected mutation carrier, who developed arthritis and erythema nodosum during the 499 
treatment (E.II.3). In two affected mutation carriers sirolimus treatment was discontinued due to 500 
ineffectiveness for cytopenia (GG.II.1), or due to increased blood pressure on the background of a 501 
renal impairment (B.II.4). In one affected mutation carrier CMV copies rose under sirolimus 502 
treatment in combination with methylprednisolone (DD.II.1), in one lymphopenia worsened (O.II.1), 503 
one died due to sepsis during sirolimus treatment (G.III.1), and in one sirolimus treatment was 504 
stopped due to serious respiratory infections (SS.II.1). Daily dosage ranged from 2 mg to 2.64 mg 505 
(n=5); trough levels were available for two affected mutation carriers (6,2 ng/ml and 8 ng/ml), for 506 
three affected mutation carriers target blood values were available (8-12 ng/ml (n=2); 12-15 ng/ml 507 
(n=1)). 508 
 509 
 510 
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Hematopoietic stem cell transplantation  511 
Twelve affected mutation carriers underwent alloHSCT between 10 and 50 years of age.(15) Main 512 
indications for transplantation included treatment-resistant cytopenia, enteropathy, and Hodgkin 513 
lymphoma; often combined with other autoimmune manifestations, lymphoproliferation or severe 514 
infections. Nine of these affected mutation carriers are alive, of whom three are more than five years 515 
post-HSCT and currently well off all medication (L.II.1, T.II.1, Y.II.1), and six are between 100 days and 516 
12 months post-transplant (B.II.3, L.II.2, P.II.2, W.II.2, GG.II.1, VV.II.1) (Table S2). In half of the 517 
affected mutation carriers the CTLA4 mutation was known prior to transplantation (6/12), the other 518 
half was transplanted due to the severity of their symptoms and the CTLA4 mutation was only 519 
identified after transplantation.  520 
 521 
Immunoglobulin substitution 522 
Sixty-three percent of affected mutation carriers (55/88) received immunoglobulin substitution 523 
either due to hypogammaglobulinemia or due to cytopenia. Twenty-eight affected mutation carriers 524 
had both diagnoses at the time of data collection and received immunoglobulin substitution due to 525 
both. 526 
Additional treatment options can be found in the Supplements.  527 
 528 
Chromosome 2 contiguous gene deletion involving CTLA4 529 
Two unrelated individuals have a heterozygous 2q33.2-2q33.3 deletion involving CTLA4 and present 530 
a CTLA-4 insufficiency-like phenotype, which is possibly influenced by the deletion of additional 531 
genes including CD28 and ICOS (Supplements). 532 
 533 
Mutation carriers who did not seek medical attention 534 
We identified 43 unaffected family members carrying the same CTLA4 mutation as their affected 535 
relatives. The treating physician of the affected mutation carrier classified family members as 536 
unaffected if they did not repeatedly seek medical care, were not under a long-term drug regimen 537 
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due to CTLA-4 insufficiency-related symptoms, or if they were not restricted in their health-related 538 
quality of life due to their symptoms. Their median age at evaluation was 46 (6 to 87) years, hence in 539 
most cases beyond the median age of manifestation. Upon thorough questioning and clinical 540 
investigation, seven carriers had diarrhea without weight loss, two had atrophic gastritis or 541 
pernicious anemia, and one had coeliac disease. Three carriers had respiratory infections and in one 542 
clinically unapparent pulmonary nodules were detected on a routine scan. Nine had dermatological 543 
involvement (psoriasis, eczema, vitiligo), and two hypothyroidism. One carrier developed colon 544 
cancer aged 78, which was successfully treated by surgery but is otherwise healthy at currently 87 545 
years of age (A.I.2). Four carriers (without recurrent infections) had IgA-deficiency, one each had low 546 
IgG or IgM, and one had low IgA and IgM, possibly contributing to respiratory infections (R.III.1). 547 
Twenty-six carriers were reported to be clinically completely healthy. 548 
Their immunological phenotyping revealed similarities to affected mutation carriers, including a 549 
decrease in NK and CD19+ B cells, but also differences, including significantly higher CD4+ T cells 550 
counts, and a higher percentage of switched memory B cells. There was no significant difference with 551 
regard to the Treg percentages in affected mutation carriers (Figure S2). 552 
 553 
  554 
 555 
 556 
 557 
 558 
 559 
 560 
 561 
 562 
 563 
 564 
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Discussion  565 
In our work, we estimate the clinical penetrance of CTLA-4 insufficiency to be around 67%; however, 566 
as genetic analysis could not be performed in all healthy first degree family members, ascertainment 567 
was incomplete. Once symptoms have occurred, the clinical course can be severe and was fatal in 15 568 
affected mutation carriers (16%).  569 
The clinical phenotype was characterized by infections, autoimmunity, and lymphoproliferation, 570 
affecting various organ systems. Affected mutation carriers have an elevated risk to develop 571 
malignancies and for EBV reactivation highlighting the importance of monitoring EBV and possibly 572 
CMV viral load, especially under immunosuppressive treatment. Cytopenia and enteropathy were 573 
the most life-threatening and treatment-resistant manifestations. This is evidenced by the fact that 574 
cytopenia was one of the main indications for alloHSCT (7/12), and half of the deceased affected 575 
mutation carriers died following a history of enteropathy and associated complications. Initial 576 
symptoms were diverse, emphasizing the importance of raising awareness of this immunodeficiency 577 
not only among immunologists but also other specialists including hematologists, neurologists, 578 
gastroenterologists, pathologists, dermatologists, and chest physicians. As the age of onset in 75% of 579 
affected mutation carriers is under the age of 18 years, CTLA-4 insufficiency should be considered in 580 
children with severe immune dysregulation of unknown origin. Also in individuals being evaluated for 581 
IBD, CVID, and ALPS, CTLA-4 insufficiency should be considered. 582 
To diagnose CTLA-4 insufficiency, we recommend sequencing the four exons of CTLA4 and then 583 
testing the effect of identified mutations on the protein by measuring CTLA-4 expression or CTLA-4-584 
mediated transendocytosis.(24) Both were reduced in all analyzed mutation carriers, but because 585 
this is also seen in individuals with mutations in other genes such as LRBA(25), these functional tests 586 
cannot be used as the only diagnostic tool to screen for CTLA4 mutations. In addition to the clinical 587 
presentation, an autosomal dominant family history can hint towards CTLA-4 insufficiency.  588 
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The immunological phenotype revealed perturbed T and B cell homeostasis and significantly 589 
increased Treg percentages within the CD4+ T cell compartment. The latter may be a transient or 590 
permanent compensatory mechanism of the CTLA-4-deficient immune system to counteract the 591 
immune-activation. The expanded and activated effector T cells may produce a cytokine profile 592 
leading to an increased Treg cell polarization in order to counterbalance the accelerated immune 593 
activation. Elevated double negative T cell counts in CTLA4 mutation carriers should prompt 594 
investigators to evaluate proposed ALPS diagnostic criteria. (26) 595 
We present first insights into targeted therapeutic strategies: Out of thirteen affected mutation 596 
carriers treated with CTLA-4-Fc, eleven responded favorably, especially enteropathy improved. 597 
Further clinical studies are necessary to determine the effectiveness and safety of CTLA-4-Fc 598 
treatment for individual clinical manifestations. Out of twelve affected mutation carriers undergoing 599 
alloHSCT, nine are alive and well (15); although long-term survival still has to be determined, 600 
alloHSCT should be considered as a treatment option in carefully selected affected mutation carriers.  601 
In individuals presenting with immunodeficiency, autoimmunity, and lymphoproliferation with 602 
impaired Treg development or function, besides CTLA-4 insufficiency, also mutations in FoxP3, LRBA, 603 
IL2RA, FAS-L, FAS, PI3K, NFKB1 and 2, STAT3, and STAT5b should be considered as a differential 604 
diagnosis.(6),(25, 27-34) Mutations in FOXP3 lead to a loss of Treg cells and cause IPEX which is an X-605 
linked condition and characterized by enteropathy, immune dysregulation, and polyendocrinopathy, 606 
but has an earlier onset, and complete penetrance.(27, 34) Immunological findings in IPEX-syndrome 607 
include normal lymphocyte counts and immunoglobulin levels in contrast to CTLA-4 insufficiency. In 608 
LRBA deficiency lysosomal CTLA-4 degradation is accelerated and CTLA-4 trafficking to the cell 609 
surface is disturbed; hence the inhibitory function of Treg cells is impaired. (25) Biallelic LRBA 610 
mutations most often lead to complete absence of the LRBA protein; affected mutation carriers 611 
present with a phenotype very similar to CTLA-4 insufficiency, characterized by various autoimmune 612 
features, lymphoproliferation with dysregulated Treg function, and a defect in production cell 613 
homeostasis,(28, 31, 32, 35-44) albeit with an earlier onset, complete penetrance and an autosomal 614 
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recessive inheritance. In addition, germline gain-of-function mutations in STAT3 lead to a broad 615 
range of autoimmune disorders such as autoimmune cytopenias and multiorgan autoimmunity (lung, 616 
gastrointestinal, hepatic, and endocrine), in combination with an increased susceptibility to 617 
infections and a short stature. Further, STAT3 gain-of-function mutations lead to secondary defects in 618 
STAT5 and STAT1 phosphorylation and impair the Treg compartment.(29, 33) 619 
As our results were collected retrospectively, several limiting factors should be considered:  affected 620 
mutation carriers were treated and evaluated by different physicians and medical departments 621 
worldwide. This can lead to an incomplete picture of the clinical phenotype. Also, data was collected 622 
at one time point, which often makes it difficult to reconstruct whether symptoms or the 623 
immunological phenotype are due to immunosuppressive treatment or the natural course of this 624 
immunodeficiency.  625 
In LRBA deficiency, sIL2R, a biomarker for T cell-mediated inflammation, decreases on abatacept 626 
treatment.(25) In our cohort sIL2R was only sporadically measured; in one affected mutation carrier 627 
sIL2R levels dropped while being on abatacept treatment. Systematical measurement of sIL2R should 628 
be considered in all mutation carriers to see whether it indicates disease activity. Affected and 629 
unaffected mutation carriers both show impaired in vitro CTLA-4 function, indicating the presence of 630 
additional factors influencing the clinical phenotype and penetrance such as environmental, genetic, 631 
or epigenetic differences. Ethnicity and origin of the mutation carriers could influence age of onset, 632 
penetrance, and severity of disease-related symptoms. We cannot assess this, as the world-wide 633 
distribution in our study is not equal and the diverse countries of origin varied in diagnostic 634 
procedures and standards. In general, there could either be one single modifier, or multiple 635 
interacting factors influencing the clinical phenotype. The latter could explain the highly variable 636 
expressivity of the phenotype. Another hypothesis suggests an internal threshold within the immune 637 
system of CTLA-4-insufficient individuals. Once it is exhausted, immune dysregulation cannot be 638 
contained by the organism and individuals develop symptoms; this could explain why healthy 639 
mutation carriers may develop life-threatening symptoms late in life (e.g. patient B.II.3 developed 640 
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hemophagocytic lymphohistiocytosis and Hodgkin lymphoma at the age of 50 years). These cases 641 
teach us to carefully monitor all first-degree relatives for CTLA-4-associated disease activity, while 642 
the search for modifying factors in CTLA-4 insufficiency continues.  643 
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Figure legends 821 
Figure 1. Pedigrees of families with CTLA-4 insufficiency 822 
Pedigrees of all families with more than one CTLA4 mutation carrier. Squares, male subjects; circles, 823 
female subjects; black filled symbols, mutation carriers classified as affected; gray filled symbols, 824 
mutation carriers classified as unaffected; slashed symbols, deceased subjects; *, sequencing of 825 
CTLA4 was performed; §, genotype inferred from clinical symptoms. 826 
 827 
Figure 2. Age of onset and age of death in CTLA-4 insufficient individuals 828 
A. Kaplan Meier curve of age of onset of CTLA4 mutation carriers (n=85).  829 
B. Age of death in affected (n=86) versus unaffected mutation carriers (n=39). 830 
 831 
Figure 3. Heterozygous germline mutations within the CTLA4 gene are distributed throughout 832 
exon 1-3.  833 
Figure 3 shows the distribution of the heterozygous germline mutations throughout the CTLA4 gene. 834 
Eight mutations are located in exon 1, 31 are located in exon 2, and six are located in exon 3. §, 835 
mutation was functionally tested by transendocytosis assay. 836 
 837 
Figure 4. Main clinical findings in CTLA-4 insufficiency 838 
Percentage distribution of clinical manifestations within affected mutation carriers. Clinical data was 839 
available for 71 to 90 affected mutation carriers. 840 
 841 
Figure 5. Exemplary findings upon CT and MRI in CTLA-4-insufficient individuals 842 
Panel A: splenomegaly (17.5 cm in diameter) and lymphadenopathy in A.III.3. Panel B: large 843 
pneumatocele following necrotizing pneumonia in PP.II.1. Panel C: CT scan of ZZ.II.1 showing 844 
peripheral bronchiectasis with inflammatory nodules in all lobes of the lung. Panel D: bronchiectasis 845 
with peribronchial ground glass nodules in keeping with bronchiolitis in XX.II.1. Panel E: multiple 846 
inflammatory nodules in O.II.1. Panel F: signal change in the right temporal lobe and cerebellum 847 
consistent with inflammation in KK.II.1. Panel G: enhancement in the thoracic cord in keeping with 848 
 31 
inflammation in KK.II.1. Panel H: signal change and swelling in the cerebellum in keeping with 849 
inflammation in P.II.2. 850 
 851 
Figure 6. Lymphocytic infiltrations and loss of EBV control define the spectrum of 852 
inflammatory and neoplastic lesions 853 
Panel A and B: lung samples of PP.II.1 and KK.II.1 with follicular bronchitis/ bronchiolitis, 854 
respectively. Lymphoid follicles are marked by asterisks. In Panel A, the follicle contains a germinal 855 
center. Panel C: EBV-coded small RNAs (EBER) positive nuclei (dark blue staining) of an early 856 
invasive gastric adenocarcinoma of B.II.4. Panel D: autoimmune gastritis with severely atrophic 857 
mucosa of the stomach, antral metaplasia and numerous intraepithelial CD8+ T cells (brown staining) 858 
of B.II.4. Panel E: nodular T cell lymphocytosis (brown staining) in the bone marrow of Z.II.2. Panel 859 
F: perivascular lymphocytes in the brain tissue of KK.II.1 (arteriolar wall highlighted by arrowhead, 860 
lumen marked by asterisk). Panel G and H: Hodgkin lymphoma in a lymph node excision sample of 861 
MM.II.1. Reed-Sternberg cell is highlighted by an arrowhead (G) or CD30 immunohistochemistry 862 
(red staining in H). Nuclei of Hodgkin cells and Reed-Sternberg cells were positive for EBER (dark 863 
blue staining, inlet H). 864 
 865 






Table 1. Baseline description of CTLA-4-insufficient individuals 
Subject 
No. 
Case No. Age 
of 
on- 
set 
Age at 
Evaluation/ 
Death  Δ 
Sex Country of origin CTLA4-/+ 
cDNA position; 
Predicted Amino Acid change 
Type of 
mutation 
Reference 
   1  A.I.2 # 87 F Germany ¶ c.105C>A; p.C35*; § Nonsense  Schubert et al. (2) 
   2  A.II.2 # 60 M Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
   3  A.II.3 # 59 F Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
   4  A.II.5 41 56 M Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
   5  A.II.8 12 ϯϰ Δ M Germany ¶    Schubert et al. (2) 
   6  A.II.9 17 ϯϳ Δ F Germany ¶ c.105C>A; p.C35*; §   Nonsense Schubert et al. (2) 
   7  A.II.10 # 49 M Germany ¶ c.105C>A; p.C35*; §  Nonsense Schubert et al. (2) 
   8  A.III.1 10 28 F Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
   9  A.III.3 15 20 M Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
10  A.III.5 # 23 F Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
11  A.III.6 # 20 F Germany ¶ c.105C>A; p.C35*; § Nonsense Schubert et al. (2) 
12  B.I.1 # ϲϲ Δ M Germany ¶    Schubert et al. (2) 
13  B.II.1 # 57 F Germany ¶ c.109+1G>T; § Splice-site  Schubert et al. (2) 
14  B.II.2 15 Ϯϯ Δ M Germany ¶    Schubert et al. (2) 
15 B.II.3 50 51 M Germany ¶ c.109+1G>T; § Splice-site  Schubert et al. (2) 
16 B.II.4 34 43 F Germany ¶ c.109+1G>T; § Splice-site  Schubert et al. (2) 
17 B.III.2 10 ϭϲ Δ F Germany ¶    Schubert et al. (2) 
18 B.III.3 # 17 F Germany ¶ c.109+1G>T; § Splice-site  Unpublished 
19 C.II.3 7 ϮϬ Δ F Greece ¶ c.208C>T; p.R70W; § Missense Schubert et al. (2) 
20 C.II.4 # 13 F Greece ¶ c.208C>T; p.R70W; § Missense Schubert et al. (2) 
21 D.I.2 # 43 F India/UK Ώ c.371A>C; p.T124P; § Missense Schubert et al. (2) 
22 D.II.1 10 22 F India/UK Ώ c.371A>C; p.T124P; § Missense Schubert et al. (2) 
23 E.II.3 10 22 F Georgia ¶ c.223C>T; p.R75W; § Missense Schubert et al. (2) 
24 F.II.1 8 Ϯϯ Δ M Germany ¶ c.2T>C; p.?; § Missense Schubert et al. (2) 
25 G.II.1 # 53 F USA¶ c.179; A<G; p.Y60C Missense Zeissig et al. (3) 
26 G.III.1 12 24 Δ F USA¶ c.179; A<G; p.Y60C Missense Zeissig et al. (3) 
27 G.III.2 1.83 22 M USA¶ c.179; A<G; p.Y60C Missense Zeissig et al. (3) 
28 H.I.2 22 52 F Germany ¶ c.407C>T; p.P136L Missense Unpublished 
29  H.II.1 10 Ϯϭ Δ M Germany ¶   Unpublished 
30 H.II.2 7 26 M Germany ¶ c.407C>T; p.P136L Missense Unpublished 
31 J.I.2 # 50 F Germany ¶ c.373G>A; p.G125R Missense Unpublished 
32 J.II.1 11 22 M Germany ¶ c.373G>A; p.G125R Missense Unpublished 
33  K.II.1 26 ϱϯ Δ F Germany ¶ c.308G>C; p.C103S Missense Unpublished 
34 L.I.2 20 ϰϬ Δ F UK ¶ c.437G>T; p.G146V Missense Slatter, et al. (15) 
35 L.II.1 5 20 F UK ¶ c.437G>T; p.G146V Missense Slatter, et al. (15) 
36 L.II.2 14 16 M UK ¶ c.437G>T; p.G146V Missense Slatter, et al. (15) 
37 M.II.3 10 ϯϱ Δ M Japan Ώ c.76_77insT; p.F28Sfs*40 Frameshift Hayakawaet al.(16) 
38 N.I.2 # 71 F Japan Ώ c.529_530insA; p.Y177* Nonsense Unpublished 
39 N.II.1 # 47 F Japan Ώ c.529_530insA; p.Y177* Nonsense Unpublished 
40 N.II.3 # 42 M Japan Ώ c.529_530insA; p.Y177* Nonsense Unpublished 
41 N.III.2 10 10 M Japan Ώ c.529_530insA; p.Y177* Nonsense Unpublished 
42 O.II.1 8 13 M Spain ¶ c.342_342delC; p.T115Lfs*5 Frameshift Unpublished 
43 P.II.2 2 13 M Germany ¶ c.534C>G; p.S178R Missense Unpublished 
44 Q.II.1 10 ϭϱ Δ M UK ¶ c.529T>G; p.Y177D Missense Slatter, et al. (15) 
45 R.II.5 24 44 F Italy ¶ c.410C>T; p.P137L Missense Unpublished 
46 R.III.1 # 18 F Italy ¶ c.410C>T; p.P137L Missense Unpublished 
47 S.II.1 2 22  M UK ¶ c.410C>G; p.P137R Missense Slatter, et al. (15) 
48 T.II.1 1.5 21 M UK ¶ c.518G>A; p.G173E Missense Slatter, et al. (15) 
49 U.I.1 # 40 M Japan Ώ c.494G>A; p.W165* Nonsense Unpublished 
50 U.II.1 3.75 9 M Japan Ώ c.494G>A; p.W165* Nonsense Unpublished 
51 U.II.2 # 8 M Japan Ώ c.494G>A; p.W165* Nonsense Unpublished 
52 U.II.3 # 6 F Japan Ώ c.494G>A; p.W165* Nonsense Unpublished 
53 V.II.1 9 14 F Japan Ώ c.436G>A; p.G146R Missense Unpublished 
54 W.I.1 19 43 M Japan Ώ c.34C>T; p.Q12* Nonsense Unpublished 
55 W.II.1 # 16 M Japan Ώ c.34C>T; p.Q12* Nonsense Unpublished 
56 W.II.2 9 14 F Japan Ώ c.34C>T; p.Q12* Nonsense Unpublished 
57 W.II.3 4 6 F Japan Ώ c.34C>T; p.Q12* Nonsense Unpublished 
58 X.I.2 # 55 F USA ΐ c.223C>T; p.R75W; § Missense Kucuk et al. (18) 
59 X.II.1 6 15 F USA ΐ c.223C>T; p.R75W; § Missense Kucuk et al. (18) 
60 Y.I.1 uk 49 M Germany ¶ c.226C>T; p.Q76* Nonsense Unpublished 
61 Y.II.1 10 20 M Germany ¶ c.226C>T; p.Q76* Nonsense Unpublished 
62 Z.I.2 # 81 F Norway ¶ c.94_101delinsTTCTCTTCATCA; 
p.P32Ffs*29 
Frameshift Unpublished 
63 Z.II.1 # 50 F Norway ¶ c.94_101delinsTTCTCTTCATCA; 
p.P32Ffs*29 
Frameshift Unpublished 
64 Z.II.2 43 49 M Norway ¶ c.94_101delinsTTCTCTTCATCA; Frameshift Unpublished 
p.P32Ffs*29 
65 Z.II.3 # uk F Norway ¶ c.94_101delinsTTCTCTTCATCA; 
p.P32Ffs*29 
Frameshift Unpublished 
66 Z.II.6 # uk M Norway ¶ c.94_101delinsTTCTCTTCATCA; 
p.P32Ffs*29 
Frameshift Unpublished 
67 Z.III.1 16 21 F Norway ¶ c.94_101delinsTTCTCTTCATCA; 
p.P32Ffs*29 
Frameshift Unpublished 
68 AA.III.3 # 46 M Japan Ώ c.155G>V; p.G52V Missense Unpublished 
69 AA.IV.1 18 18 M Japan Ώ c.155G>V; p.G52V Missense Unpublished 
70 BB.I.2 uk 45 F Japan Ώ c.119T>C; p.V40A Missense Unpublished 
71 BB.II.1 # 20 F Japan Ώ c.119T>C; p.V40A Missense Unpublished 
72 BB.II.2 10 17 F Japan Ώ c.119T>C; p.V40A Missense Unpublished 
73 CC.II.1 10 43 F Japan Ώ c.25_26insACAAGGCTCAGCTG; 
p.N14Tfs*5 
Frameshift Unpublished 
74 DD.I.2 # 37 F Japan Ώ c.232_232delG; p.D78Tfs*4 Frameshift Unpublished 
75 DD.II.1 13 15 M Japan Ώ c.232_232delG; p.D78Tfs*4 Frameshift Unpublished 
76 EE.II.1 11 18 M TheNetherlands¶ c.436G>T; p.G146*
 
Nonsense Unpublished 
77 FF.II.1 6 ϮϮ Δ M USA c.208C>T; p.R70W; § Missense Unpublished 
78 GG.I.1 # 47 M Germany ¶ c.347T>C; p.I116T; § Missense Unpublished 
79 GG.II.1 9 20 F Germany ¶ c.347T>C; p.I116T; § Missense Unpublished 
80 GG.II.2 # 18 M Germany ¶ c.347T>C; p.I116T; § Missense Unpublished 
81 GG.II.3 # 14 F Germany ¶ c.347T>C; p.I116T; § Missense Unpublished 
82 HH.II.1 2 28 F USA ΐ c.254G>A; p.C85Y Missense Unpublished 
83 JJ.II.1 11 28 M Germany ¶ c.223C>T; p.R75W; § Missense Unpublished 
84 KK.I.1 # 58 M Czech Republic ¶ c.402_415del; p.M123Ifs*15 Frameshift Unpublished 
85 KK.II.1 21 36 F Czech Republic ¶ c.402_415del; p.M123Ifs*15 Frameshift Unpublished 
86 LL.II.1 1 ϭϰ Δ F Czech Republic ¶ c.407C>T; p.P136L Missense Unpublished 
87 MM.II.1 14 38 M Germany¶ c.530_543del; p.F179Cfs*29 Framshift Unpublished 
88 NN.I.1 12 61 M Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
89 NN.II.1 # uk F Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
90 NN.II.6 23 29 F Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
91 NN.II.8 13 20 F Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
92 NN.II.9 18 23 M Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
93 NN.II.10 # 17 F Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
94 NN.II.11 6 21 M Uruguay¶ c.280G>T; p.E94* Nonsense Unpublished 
95 OO.II.1 18 24 M Germany¶ c.224G>A; p.R75Q, § Missense Unpublished 
96 PP.II.1 8 40 M Canada¶ c.406C>T; p.P136S Missense Unpublished 
97 QQ.II.1 13 31 M Germany¶ c.410C>T; p.P137L Missense Unpublished 
98 RR.II.1 14 16 F USA¶ c.356T>G; p.L119R Missense Unpublished 
99 SS.II.1 15 27 F USA¶ c.436G>A; p.G146R Missense Unpublished 
100 TT.I.1 5 50 M Czech Republic¶ c.178T>A; p.Y60N Missense Unpublished 
101 TT.II.2 21 26 M Czech Republic¶ c.178T>A; p.Y60N Missense Unpublished 
102 TT.II.3 11 24 F Czech Republic¶ c.178T>A; p.Y60N Missense Unpublished 
103 TT.II.4 4 10 M Czech Republic¶ c.178T>A; p.Y60N Missense Unpublished 
104 TT.II.5 1 6 M Czech Republic¶ c.178T>A; p.Y60N Missense Unpublished 
105 UU.II.1 # ϴϲ Δ F Spain¶   Unpublished 
106 UU.II.2 40 73 F Spain¶   Unpublished 
107 UU.III.2 6 65 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
108 UU.III.3 59 ϲϬ Δ F Spain¶   Unpublished 
109 UU.III.4 57 68 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
110 UU.III.6 # 62 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
111 UU.III.7 14 63 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
112 UU.III.9 uk 55 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
113 UU.III.10 # 53 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
114 UU.IV.1 # 46 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
115 UU.IV.2 31 42 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
116 UU.IV.3 # 40 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
117 UU.IV.4 # 33 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
118 UU.IV.9 # 40 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
119 UU.IV.10 uk uk M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
120 UU.IV.12 0.25 34 F Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
121 UU.V.1 0.25 10 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
122 UU.V.2 0.83 3 M Spain¶ c.223C>T; p.R75W; § Missense Hou et al. (17) 
123 VV.I.1 # uk M Saudi Arabia¶ c.359_359delG; p.A121fs*23 Frameshift Unpublished 
124 VV.II.1 7 13 M Saudi Arabia¶ c.359_359delG; p.A121fs*23 Frameshift Unpublished 
125 WW.II.1 8 12 M UK¶ c.410C>G; p.P137R Missense Unpublished 
126 XX.II.1 12 40 M Belgium¶ c.407C>T; p.P136L Missense Unpublished 
127 YY.II.1 3 14 F Germany¶ c.326G>A; p.G109E; § Missense Unpublished 
128 ZZ.I.2 uk 39 F Germany¶ c.151C>T; p.R51* Nonsense Unpublished 
129 ZZ.II.1 16 19 M Germany¶ c.151C>T; p.R51* Nonsense Unpublished 
# = unaffected Mutation carrier;  = died prior to being genotyped; Δ = deceased due to disease 
associated manifestations or complications; age at death is shown; ¶= Caucasian; Ώ= Asian; ΐ = 
African-American; § = disease causing effect of the mutation is functionally proven by 
transendocytosis assay ;Figure SϮͿ; Ω = Pϭ and PϮ with Chromosome 2 contiguous gene deletion 
involving CTLA4 are not included within all calculations of the clinical spectrum. UK = United 
Kingdom, uk = unknown. F = female, M =male, USA = United States of America 
 
130 AAA.II.1 23 46 M Switzerland¶ c.257C>T; p.A86V; § Missense Navarini et al. (19) 
131 BBB.II.1 1 17 F USA¶ c.56_57insCTGG; p.T19Tfs*42 Frameshift Unpublished 
132 CCC.II.1 14 14 M USA¶ c.406C>G;p.P136A Missense Unpublished 
133 DDD.II.1 38 38 F USA¶ c.173G>T; p.C58F Missense Unpublished 
[Chr2_1 P1 5 37 F Canada¶ 2q33.2-2q33.3 Deletion Unpuplished] Ω 
[Chr2_2 P2 14 20 M Australia¶ 2q33.2-2q33.3 Deletion Unpublished] Ω 
Total 
no: 133 
54 different 
families  
Penetrance 
90 affected 
mutation 
carriers 
67.6% 
66 Female 
67 Male 
45 different mutations  
28 novel mutations 
82 unpublished 
mutation carriers 
Table 2. Mutations identified in multiple families. 
Exon AA position Mutations  Families 
2 60 p.Y60C (c.179A>G); 
p.Y60N (c.178T>A) 
Family G; 
Family TT 
2 70 p.R70W (c.208C>T) Family C, Family FF 
2 75 p.R75W (c.223C>T); 
p.R75Q (c.224G>A) 
Family E, Family X, Family JJ, Family UU; 
Family OO 
2 136 p.P136L (c.407C>T); 
p.P136A (c.406C>G); 
p.P136S (c.406C>T) 
Family H, Family LL, Family XX; 
Family CCC; 
Family PP 
2 137 p.P137L (c.410C>T); 
p.P137R (c.410C>G)  
Family R, Family QQ; 
Family S, Family WW 
2 146 p.G146* (c.436G>T); 
p.G146R (c.436G>A); 
p.G146V (c.437G>T) 
Family EE 
Family V, Family SS 
Family L 
2 177 p.Y177* (c.529_530insA); 
p.Y177D (c.529T>G) 
Family N; 
Family Q 
At seven loci mutations were identified in multiple families. 
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Methods 
We report on 133 individuals, including 90 affected and 43 unaffected mutation carriers (relatives who did not 
seek medical attention) from diverse ethnic backgrounds (Table 1). Twenty-six out of the 43 unaffected carriers 
were classified as completely unaffected as they were reported to be completely free of CTLA-4 associated 
symptoms. One-hundred-twenty-five individuals were genetically proven heterozygous CTLA4 mutation 
carriers; eight were relatives who had that deceased prior to being genotyped without availability of genomic 
DNA. They were either diagnosed with CTLA-4 insufficiency following their typical clinical presentation, or 
they were mandatory mutation carriers following Mendelian inheritance. Fifty-one mutation carriers have 
previously been published (1-9) and 99 individuals are here described for the first time. 
All samples were donated following informed written consent under local ethics board–approved protocols 
239/99_BG, 251/13_KW, and 282/11_SE version 140023. Written consent was obtained of all included 
individuals or their legal guardians. This research was performed following approved protocols of the Albert-
Ludwigs-Universität Freiburg, Germany. 
Samples and clinical information were collected between October 2014 and July 2016. For all individuals, 
treating physicians completed a detailed questionnaire including genetics, clinical history, laboratory values, 
treatment, and outcome. Immunoglobulin levels under replacement therapy and B cell values after rituximab 
treatment were excluded. For some affected mutation carriers, treating physician could not provide us with the 
exact immunoglobulin serum levels but only with the information whether IgG, IgM and IgA were reduced. We 
included available serum levels in Figure S2 whereas Figure 4 includes all affected mutation carriers with 
hypogammaglobulinemia. 
Mutation carriers were classified as affected mutation carried if they showed clinically apparent symptoms 
related to CTLA-4 deficiency requiring medical care or treatment. Lymphocyte phenotyping, CTLA-4 staining, 
and transendocytosis assay were performed in selected individuals as previously described.(4, 10) Statistical 
analysis was performed using GraphPad Prism version 6, and p values were calculated by two-tailed unpaired 
Student's t-test for the means with a 95% confidence interval, and Fisher's exact test for probing the gender bias, 
assuming the null hypothesis that male and female mutation carriers are equally affected. CVID was diagnosed 
on the basis of the revised European society of immune deficiencies (ESID) registry. (11)  
 
Case vignettes 
Case vignette – Respiratory involvement 
PP.II.1 presented aged 17 with cough and dyspnea and was treated with multiple antibiotics. X-ray revealed 
confluent opacities and lung biopsy showed a mixed cellular and follicular bronchiolitis (Figure 6 Panel A) and 
EBV+ lymphocytic T cell infiltrations, consistent with bronchiolitis obliterans organized pneumonia (BOOP). 
He was therefore treated with prednisone; whenever trying to wean him off prednisone other symptoms (e.g. 
arthritis, uveitis) appeared and he became steroid dependent. He had multiple pneumonias, including one episode 
of necrotizing pneumonia with cavitation at age 38 (see Figure 5 Panel B). 
 
Case vignette – Gastrointestinal involvement 
HH.II.1 first presented at age two with diarrhea. Throughout the next years she developed malabsorption and 
nutritional deficiencies necessitating total parenteral nutrition (TPN) for prolonged periods of time. Biopsies 
revealed villous blunting in the small bowel, apoptotic bodies in the colonic mucosa, and CD3+CD8+ 
infiltrations in the small and large bowel. In her twenties, enteropathy worsened with eight stools per day 
requiring potassium and magnesium replacement in addition to TPN. Treatment including steroids, calcineurin 
inhibitors, mycophenolate, methotrexate, TNF-alpha inhibitors, rituximab, and ustekinumab had no lasting 
effect. Following genetic diagnosis at age 29, abatacept was started. On abatacept she is doing well, stool 
frequency decreased from eight to four stools per day, she reported to have the first formed stools since early 
childhood, and is off TPN and intravenous electrolyte replacement. 
 
Case vignette – Cytopenia 
GG.II.1 presented aged nine with petechial bleeding and platelets 2/nl. ITP was diagnosed and treated with high-
dose steroids. Within the next two years she had relapsing episodes of ITP and AIHA. Treatment with steroids 
and immunoglobulins was only intermittently effective. At the age of eleven years, the platelet count was 10/nl 
and she developed cerebral bleeding leading to seizures and transient hemiparesis. Over the next years, treatment 
including plasmapheresis, rituximab, methotrexate, cyclosporin, sirolimus and abatacept had no long-lasting 
effect. Aged 15, she developed autoimmune neutropenia. Following a severe autoimmune hemolytic episode at 
age 18 (Hb 21g/l) and cerebral vasculitis resulting in paraparesis, she had a splenectomy and ultimately 
underwent successful alloHSCT at age 20.  
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Case vignette – Neurological involvement 
KK.II.1 presented aged 30 with headache and Bell’s palsy. MRI imaging revealed multiple supra- and 
infratentorial lesions of unknown etiology (Figure 5 Panel F) and steroid treatment was started after excluding 
borreliosis in the cerebrospinal fluid. Clinical response was incomplete and ten days prior to biopsy, steroid 
treatment was discontinued leading to a worsening of the CNS lesions and development of lower extremity 
paraparesis. The biopsy revealed non-malignant perivascular infiltration of lymphocytes (Figure 6 Panel F), 
immunohistochemically CD3+CD8+ T cells. Following the brain biopsy, steroid treatment was restarted and led 
to partial improvement of the paraparesis. Two weeks later, magnetic resonance imaging revealed spinal cord 
inflammation (Figure 5 Panel G) and she developed palsy of the musculus sphincter ani. Currently, aged 36, she 
is on 8 mg of methylprednisolone per day. Repeat MRI shows partial regression of the lesions, and she can walk 
without support, while fecal incontinence remains. 
 
Case vignette – Treatment 
B.II.4 had CVID, wasting diarrhea and developed EBV-associated gastric cancer aged 41, which was resected. 
Abatacept was started, and after three months stool frequency normalized and she regained 18 kg of weight. 
Immunological findings included a decrease in the MFI of activation markers CD4+HLA-DR+ and CD8+HLA-
DR+ and CD21low B cells while total B cells normalized (Figure S1). After one year, abatacept was 
discontinued due to elevated EBV copies up to 12,000 copies/ml, and switched to Rituximab under which EBV 
was cleared in blood, but stool became loose, stool frequency rose, and Helicobacter pylori associated gastritis 
occurred. 
 
Additional treatment options 
Seventy percent of affected mutation carriers received corticosteroids (60/86), including 46 affected mutation 
carriers requiring long-term treatment and 41 undergoing pulse treatment. Forty-eight affected mutation carriers 
had at least one course of immunosuppressive steroid-sparing agents for autoimmune or inflammatory 
conditions. B cells are potent APCs (12), which, once activated, express the co-stimulatory B7-molecules (CD80 
and CD86), binding and stimulating CD28 and not being sufficiently counteracted by CTLA-4 in case of CTLA4 
mutations. Anti-CD-20 treatment with rituximab efficiently depletes these potent immune-stimulatory cells and 
is frequently used in the treatment of refractory cytopenias(13). In our cohort, rituximab (n=25) was used more 
often than abatacept/belatacept (n=13) and sirolimus (n=13), with thirteen affected mutation carriers responding 
with good or partial effect. These included improved pancytopenia (D.II.1), resolution of AIHA with 
concomitant permanent loss of B cells (LL.II.1), and possible contribution to improvement of enteropathy 
(WW.II.1).  
Thirty-five percent of affected mutation carriers (27/78) were under antibiotic prophylaxis. In one affected 
mutation carrier treatment with vedolizumab (blocking α4β7 integrin(14)) improved colitis, and in the same 
individual PRCA responded well to cyclosporine A (AAA.II.1).(6)  
 
 
Chromosome 2 contiguous gene deletion involving CTLA4 
In two unrelated individuals from Canada (P1) and Australia (P2) a large heterozygous 2q33.2-2q33.3 deletion 
was detected, implicating the known immune relevant genes CTLA4, ICOS, and CD28. Whereas the mutation in 
P1 has been proven to have occurred de novo, the same deletion was detected in the clinically healthy mother of 
P2. In both ICOS was sequenced to exclude a mutation on the second allele causing ICOS deficiency(15). The 
phenotype of both individuals is characterized by immune dysregulation, similar to our cohort of affected CTLA4 
mutation carriers, even though an influence of the heterozygous loss of other genes located at this locus has to be 
considered. 
The age of onset in these two individuals was five years (P1) and 14 years (P2) respectively, and age at 
evaluation was 37 years (P1) and 20 years (P2). Clinical features common for both individuals included 
hypogammaglobulinemia, lymphoproliferation, recurrent respiratory tract infections, GLILD, and a diagnosis of 
CVID made at the age of 12 years (P1) and 14 years (P2). However, primary clinical complications were 
autoimmune enteropathy in P1 and AIHA in P2. 
P1 first presented with arthritis at the age of five years. She developed diarrhea at the age of 9, respiratory tract 
infections at the age of 12, and was further diagnosed with growth retardation. She had recurrent Varicella 
zoster- and Herpes simplex virus, and esophageal Candida infections. Her immunoglobulin levels revealed low 
IgG (1.73 g/l) and low IgA (0.11 g/l) at the age of 25 years. At 32 years she had recurrent fevers and at 36 years 
she presented with seizures. Infiltrations into the brain were described at that time but were not further 
investigated. Lymphocytic infiltrations into gastrointestinal tract, lung, and kidney were confirmed by biopsy. 
This individual received rituximab for one year without clinical improvement and was further treated with 
abatacept, corticosteroids, immunoglobulin substitution, and prophylactic antibiotics. At age 37, anticoagulation 
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was stopped following a traumatic leg hematoma. A few months later she developed acute severe dyspnea, chest 
pain, hypoxemia, and suddenly died. Autopsy was not performed. 
P2 had recurrent respiratory tract infections, developed AIHA at the age of 14 years, splenomegaly at the age of 
16, and GLILD at the age of 17: biopsy revealed B and T cell infiltrations. At that time, he had low IgG (1.43 
g/l), low IgM (0.24 g/l), and low IgA (<0.05 g/l), after being treated with one course of rituximab at age 14 for 
his AIHA. At age 19, blurred vision of the right eye and bilateral optic disc swelling led to magnetic resonance 
imaging and revealed a swollen right ocular medial rectus muscle, responding to methylprednisolone/sirolimus 
treatment. 
 
 
Possible influences of disease manifestation   
As the penetrance of CTLA-4 insufficiency is incomplete, we searched for modifying factors predicting overt 
disease.  
We saw an association between male gender and the occurrence of clinical symptoms, as 76% (51/67) of male, 
but only 59% (39/66) of female mutation carriers were classified as affected. This difference was highly 
significant (p=0.04). However, there was no gender preponderance within the 15 deceased individuals. 
We hypothesized that a second germline or somatic hit or a reversion of the mutation, the exposure to a specific 
viral infection, or the HLA locus may influence the clinical penetrance, but no correlation was found. 
Second, we hypothesized that affected individuals manifested following a second somatic genetic hit in CTLA4 
or that unaffected mutation carriers stayed healthy due to a somatic reversion of the heterozygous CTLA4 
germline mutation. To this end we sequenced isolated DNA from CD4+ T cells from five affected and eight 
unaffected mutation carriers, by next generation sequencing (Illumina MiSeq) to detect small clones of cells with 
potential biallelic mutations, but always only identified the one predicted germline mutation in CTLA4. Likewise, 
no somatic reversion was detected.  
We studied whether the affected individuals had been exposed to a different set of viral infections than the 
currently healthy individuals. This analysis was complicated by the fact that some affected individuals either 
were hypogammaglobulinemic or on immunoglobulin replacement therapy, affecting their serological response. 
However, we found that four tested unaffected individuals were EBV-positive, while four of seven tested 
affected individuals were EBV-negative. Regarding CMV, two out of four tested unaffected mutation carriers 
were CMV-positive, and two were negative. Out of six tested affected mutation carrier, only two have had a 
CMV infection. One affected mutation carrier (B.II.3) was tested for CMV both before first symptoms 
manifested and after first manifestation of CTLA-4 deficiency and results were negative at both times. 
Concerning parvovirus B19, four tested unaffected mutation carriers, as well as five affected mutation carriers 
were positive. Due to the variation of the age of onset, even within one family, a viral infection triggering the 
symptoms is not unlikely, but EBV, CMV, and parvovirus B19 are unlikely to be the underlying cause.  
We asked the question whether there is an HLA restriction within the affected or unaffected cohort, as CVID and 
IgA deficiency have previously shown strong HLA-associations.(16) However, when genotyping two of our 
largest families (A and B) for HLA-class I (HLA-A, -B, -C) and HLA-class II (HLA-DRB1*, -DQB1*) the 
individual HLA-types did not segregate with the disease phenotype. This data does not support the hypothesis of 
HLA as modifier in disease pathogenesis in families A and B. 
Last, we analyzed whole exome sequencing data from 13 affected and twelve unaffected mutation carriers to 
screen for genetic loci within the coding sequences of the human genome. However, we were unable to identify 
SNPs or Indels occurring exclusively in affected but not in unaffected mutation carriers or vice versa.  
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Figure legends 
Figure S1. CTLA-4 expression and function in heterozygous mutation carriers 
 Panel A: Mean fluorescence intensity of total CTLA-4 in CD4+CD45RO+FoxP3+ Tregs is significantly 
decreased in mutation carriers compared to wildtype controls (**** = p < 0.0001), and in affected compared to 
unaffected mutation carriers (* = p < 0.05). Panel B: Impaired CTLA-4-mediated transendocytosis of CD80-GFP 
was observed in CD4+CD45RO+FoxP3+ Tregs, after co-culture of mutation carriers’ CD4+ T cells with CHO 
cells presenting CD80-GFP. §, This mutation is already published, further information can be found in Table 1. 
Figure S2. Immunological phenotype of CTLA-4 insufficiency 
Percentages and absolute numbers of lymphocytes and various B and T cell subsets in the peripheral blood of 
affected and unaffected mutation carriers. IgA-, IgM-, and IgG serum levels in the peripheral blood of affected 
and unaffected mutation carriers [g/l]. For immunoglobulin levels only exact values were included in this figure 
(further information see methods). B cell values and immunoglobulin levels of affected mutation carriers treated 
with RTX or IVIG were excluded. Gray background indicates normal range.  
 
Figure S3. Immunological changes during abatacept treatment in affected mutation carriers B.II.4 
Panel A: Percentage of CD45RA+ cells within the group of CD4+ T cells during a time span of 400 days post 
first abatacept infusion. Panel B: Percentage of CD45RO+ cells within the group of CD4+ T cells during a time 
span of 400 days post first abatacept infusion. Panel C: Percentage of CD4+HLA-DR+ cells within the 
lymphocytes. Panel D: Mean fluorescence intensity of CD4+HLA-DR+ cells (black) and CD8+HLA-DR+ cells 
(gray). Day 1, day 142, day 290, and day 330 after starting abatacept treatment. 
 
 
 
 



Table S2. HSCT 
ID 
Gender 
Age (year) 
of HSCT 
Reason for transplantation Conditioning 
regimen 
Serotherapy GvHD 
prophylaxis 
HLA/ 
Donor 
source 
Chimerism GvHD/ 
Complications 
Outcome 
L.II.1  
Female 
10  (2005) life-threatening, multisystem 
and immune-suppressant 
drug resistant nature of her 
gastrointestinal and 
haematological disease 
Flu, Mel Alem CsA  BM 
9/10 
MUD 
100% No GvHD, 
No complications  
Alive and well 
10.5 years 
Complete remission 
L.II.2  
Male 
17 (2015) serious clinical complications 
of disease - Hodgkin disease 
and difficult to control 
autoinflammatory gut 
disease, mother died of 
disease, sister cured of 
disease by MUD BMT  
Treo, Flu, TT  Alem MMF, CsA BM 
10/10 
MUD 
100% Chronic GVHD from 
first week post BMT 
treated with methyl-
prednisolone and 
belatacept. Required 3-4 
months on TPN. CMV 
colitis. 
 
12 month follow-up: chronic 
CMV and gut GvHD, finally 
improving after 11 months. 
Currently fully orally fed, on 
oral budesonide 3mg/d and 
IV infliximab; 4 stools a day. 
Not requiring any treatment 
for CMV. 
Q.II.1  
Male 
15 (2008) Thrombocytopenia and 
widespread lymphoid 
hyperplasia despite 
Rituximab 
Flu, Mel Alem CsA, MMF PBSC 
10/10 
MUD 
100% Acute GvHD Grade IV 
of the gut 
Died 4 months after HSCT 
due to a GvHD disease 
S.II.1 
Male 
20 (2008) Cytopenias, bronchiectasis, 
enteropathy (TPN 
dependent); mother had died 
of GI lymphoma 
Flu, Mel Alem, CsA, MMF PBSC 
10/10 
MUD 
100% Acute Grade II skin; 
resolved 
Died 2.5 years later due to 
DKA, 
Before: complete remission 
T.II.1 
Male 
16 (2010) Arthritis, cytopenias, lymph-
adenopathy: father had died 
post autologous HSCT for 
non-Hodgkin lymphoma. 
Treo, Flu Alem CsA, MMF PBSC 
10/10 
MUD 
T 90% 
B 95% 
CD15+ 96% 
No GvHD 
CMV re-activation 
(resolved) 
1 episode of AIHA 6 
months post HSCT 
Alive and well, 6.1 years, 
Complete remission 
Y.II.1  
Male 
16 (2011) Therapy-refractory and 
partially life-threatening 
autoimmune cytopenias and 
lympho-proliferative disorder 
of unknown dignity 
Treo, Flu Alem CsA, MMF PBSC 
9/10 
MUD 
100% No GvHD 
No complications 
Alive and well 5.6 years, 
complete remission 
B.II.3   
Male 
51 (2015) Life-threatening HLH,  
Hodgkin lymphoma 
Bu, Flu, TT ATG CsA, MMF PBSC 
10/10 
MUD 
100% Acute GvHD Grade II of 
the skin. Treated with 
Steroids. 
HSV-mucositis Grade II, 
resolved 
100 day follow-up: alive and 
well 
Alem = Alemtuzumab total dose 1.0 mg/kg; Flu = Fludarabine total dose G.II.1, L.II.1, S.II.1, T.II.1, Y.II.1, LL.II.1: 150 mg/m2 B.II.3 60 mg/m2, P.II.2: 160 mg/m2; Treo = 
Treosulfan total dose 42g /m2; Mel = Melphalan total dose 140 mg/m2; TT = Thiopeta 5 mg/kg, LL.II.1: 10 mg/kg, P.II.2: 8 mg/kg; Bu = Busulfan totale dosis 6.4 mg/kg; PBSC 
= peripheral blood stem cells; BM = bone marrow; PBSC= peripheral blood stem cell; MUD= matched unrelated donor; MMUD= mismatched unrelated donor; GvHD=Graft 
versus host disease; CsA = Cyclosporin; Pred = Prednisolon; MMF= Mycophenolatmofetil; ATG= Antithymocyte globulin P.II.1: 3x15 mg/kg; DKA = diabetic ketoacidosis. 
 
P.II.2  
Male 
13 (2015) Life-threatening autoimmune 
complications including 
recurrent, treatment resistant 
cytopenias and AI-
encephalitis 
Treo, Flu, TT  ATG CsA, MTX BM 
10/10 
MUD 
100% Acute GvHD Grade II of 
the skin. Treated with 
Steroids. 
 
10 months follow-up: alive 
and well 
GG.II.1  
Female 
20 (2015) Life-threatening autoimmune 
cytopenias, hemolysis, 
vasculitis with paraplegia;  
therapy resistant, low life 
quality 
Treo, Flu, TT ATG CsA, MTX BM 
9/10 
MUD 
96% Bacterial  sepsis, Adeno-
virus-, CMV- and EBV-
re-activation requiring 
virus specific T cell 
transfer, resolved 
10 months follow-up: alive 
and well 
LL.II.1 
Female 
14 (2015) Uncontrollable CMV 
infection, immune 
deficiency, lack of B cells, 
impossibility of immuno-
suppressive therapy for lung 
disease 
Treo, Flu, TT ATG CsA, MTX PBSC 
9/10 
MUD 
100% GvHD Grade IV of the 
GIT  (bleeding, 
hyperbili-rubinemia), 
Candida dubli-niensis, 
CMV, BKV infection, 
multiple organ failure, 
cytopenia 
Died 4 months after HSCT 
due to multiple complications 
(see complications) 
W.II.2 
Female 
14 (2016) Recurrent infections Flu, Mel TBI ?? Tacrolimus, 
PT-Cy 
BM 
7/8 
MMUD 
100% Acute GvHD: skin stage 
2, Grade I 
Alive and well 7 months 
after; improvement of 
diarrhea and alopecia 
VV.II.1 
Male 
14 (2016) Drug resistant nature of 
respiratory and 
gastrointestinal disease 
Bu, Flu Alem CsA, MMF BM 
10/10 
MUD 
>97% in all 
lineages 
except T 
cells (60%) 
CMV reactivation 
despite foscarnet (42 
mg/kg) and CMV Ig. 
Treated with increased 
foscarnet (54 mg/kg).  
ARDS in the setting of 
CMV re-activation, 
successful  methyl-
prednisolone treatment 
(2 mg/kg) led to 
resolution 
Primary graft failure, remains 
lymphopenic and requires 
steroid treatment (1mg/kg) 
for pulmonary disease at day 
>100 post transplantation. 
Table S3. Frequency of genetic changes in the CTLA4 gene (Ensembl) 
Exon Variant ID Chr: bp Alleles Global MAF Highest 
population 
MAF 
(highest 
MAF in 
any data 
base) 
Conseq. Type AA AA 
cord 
Transcript 
Exon 1 (+) rs767352102 2:203867946 G/T T=0.00002/2 (ExAC); 
T=0.00003/1 (TOPMED) 
< 0.01 missense 
variant 
A/S 2 ENST00000302823.7 
Exon 1 (+) rs896306346 2:203867958 T/A A=0.00003/1 
(TOPMED) 
< 0.01 missense 
variant 
F/I 6 ENST00000302823.7 
Exon 1 (+) rs201778935 2:203867964 C/T T=0.00002/3 (ExAC); 
T=0.00008/1 (GO-ESP) 
< 0.01 missense 
variant 
R/W 8 ENST00000302823.7 
Exon 1 (§) rs138279736 2:203867965 G/A/T A=0.0006/3 (1000 
Genomes); A=0.0002/3 
(GO-ESP); A=0.00003/1 
(TOPMED) 
0.02 missense 
variant 
R/Q 8 ENST00000302823.7 
Exon 1 (§) rs138279736 2:203867965 G/A/T T=0.00005/6 (ExAC) 0.02 missense 
variant 
R/L 8 ENST00000302823.7 
Exon 1 (+) rs146541851 2:203867970 A/G G=0.000008/1 (ExAC); 
G=0.00008/1 (GO-ESP); 
G=0.0001/3 (TOPMED) 
< 0.01 missense 
variant 
K/E  10 ENST00000302823.7 
Exon 1 (§) rs755080468 2:203867979 C/T T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
L 13 ENST00000302823.7 
Exon 1 (§) rs376591332 2:203867984 C/T T=0.000008/1 (ExAC); 
T=0.00008/1 (GO-ESP) 
< 0.01 synonymous 
variant 
N 14 ENST00000302823.7 
Exon 1 (+) rs748599835 2:203867988 G/A A=0.000008/1 (ExAC) < 0.01 missense 
variant 
A/T 16 ENST00000302823.7 
Exon 1 (+) rs772433747 2:203867989 C/A A=0.00003/4 (ExAC) < 0.01 missense 
variant 
A/D 16 ENST00000302823.7 
Exon 1 (§) rs231775 2:203867991 A/G/T G=0.4112/49892 0.48 missense T/A 17 ENST00000302823.7 
(ExAC); G=0.4273/2140 
(1000 Genomes); 
G=0.3694/4805 (GO-
ESP); G=0.3890/11326 
(TOPMED) 
variant 
Exon 1 (§) rs231775 2:203867991 A/G/T  0.48 missense 
variant 
T/S 17 ENST00000302823.7 
Exon 1 (+) rs769368847 2:203868001 G/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
W/L 20 ENST00000302823.7 
Exon 1 (+) rs886041906 2:203868002 G/A NA  stop gained W/* 20 ENST00000302823.7 
Exon 1 (+) rs1041117695 2:203868004 C/G NA < 0.01 missense 
variant 
P/R 21 ENST00000302823.7 
Exon 1 (+) rs606231418 2:203868017 G/- NA  frameshift 
variant 
L/X 25 ENST00000302823.7 
Exon 1 (+) rs16840275 2:203868017 G/C C=0.0023/275 (ExAC); C=0.0064/32 
(1000 Genomes); C=0.0094/122 (GO-
ESP); C=0.0106/308 (TOPMED) 
synonymous 
variant 
L 25 ENST00000302823.7 
Exon 1 (+) rs748802696 2:203868019 T/C C=0.000008/1 (ExAC) < 0.01 missense 
variant 
F/S 26 ENST00000302823.7 
Exon 1 (§) rs145950656 2:203868029 C/T T=0.00002/2 (ExAC); 
T=0.0002/2 (GO-ESP) 
< 0.01 synonymous 
variant 
L 29 ENST00000302823.7 
Exon 1 (+) rs774434261 2:203868033 A/G G=0.000008/1 (ExAC) < 0.01 missense 
variant 
I/V 31 ENST00000302823.7 
Exon 1 (+) rs369567630 2:203868036 C/T T=0.00004/5 (ExAC); 
T=0.00008/1 (GO-ESP) 
< 0.01 missense 
variant 
P/S 32 ENST00000302823.7 
Exon 1 (§) rs767441580 2:203868038 T/C C=0.00002/2 (ExAC) < 0.01 synonymous 
variant 
P 32 ENST00000302823.7 
Exon 1 (*) rs606231420 2:203868047 C/A NA  stop gained C/* 35 ENST00000302823.7 
Exon 1 (*) rs606231421 2:203868052 G/T NA  splice donor 
variant 
  ENST00000302823.7 
Exon 2 (+) rs200180357 2:203870579 A/G/T G=0.00002/2 (ExAC); 
G=0.0002/1 (1000 
Genomes) 
< 0.01 splice region 
variant~intron 
variant 
  ENST00000302823.7 
Exon 2 (+) rs200180357 2:203870579 A/G/T  < 0.01 splice region 
variant~intron 
variant 
  ENST00000302823.7 
Exon 2 (+) rs767100685 2:203870582 C/G G=0.00002/2 (ExAC) < 0.01 splice region 
variant~intron 
variant 
  ENST00000302823.7 
Exon 2 (+) rs773279316 2:203870583 T/C C=0.000008/1 (ExAC) < 0.01 splice region 
variant~intron 
variant 
  ENST00000302823.7 
Exon 2 (§) rs760446668 2:203870593 C/T T=0.00003/3 (ExAC); 
T=0.00003/1 (TOPMED) 
< 0.01 synonymous 
variant 
H 39 ENST00000302823.7 
Exon 2 (+) rs767995794 2:203870602 GCCTGCTGTGGTACTG/- -=0.000008/1 (ExAC) < 0.01 frameshift 
variant 
QPAVVL/X 42 ENST00000302823.7 
Exon 2 (+) rs766143912 2:203870612 G/A A=0.000008/1 (ExAC) < 0.01 missense 
variant 
V/I 46 ENST00000302823.7 
Exon 2 (§) rs146200342 2:203870615 C/T T=0.00008/1 (GO-ESP) < 0.01 synonymous 
variant 
L 47 ENST00000302823.7 
Exon 2 (§) rs776726776 2:203870617 G/A A=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
L 47 ENST00000302823.7 
Exon 2 (*) rs606231417 2:203870627 C/T NA  stop gained R/* 51 ENST00000302823.7 
Exon 2 (+) rs759766975 2:203870628 G/A A=0.000008/1 (ExAC) < 0.01 missense 
variant 
R/Q 51 ENST00000302823.7 
Exon 2 (§) rs765325921 2:203870635 C/T T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
I 53 ENST00000302823.7 
Exon 2 (§) rs373393185 2:203870647 G/A A=0.00008/1 (GO-ESP) < 0.01 synonymous 
variant 
V 57 ENST00000302823.7 
Exon 2 (+) rs752811424 2:203870655 A/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
Y/F 60 ENST00000302823.7 
Exon 2 (+) rs758465752 2:203870667 G/A A=0.000008/1 (ExAC) < 0.01 missense 
variant 
G/D 64 ENST00000302823.7 
Exon 2 (§) rs979522213 2:203870674 C/T NA  synonymous 
variant 
A 66 ENST00000302823.7 
Exon 2 (§) rs764639840 2:203870677 T/G G=0.000008/1 (ExAC) < 0.01 synonymous T 67 ENST00000302823.7 
variant 
Exon 2 (+) rs557116456 2:203870681 G/A A=0.00002/2 (ExAC); 
A=0.0002/1 (1000 
Genomes);A=0.00003/1 
(TOPMED) 
< 0.01 missense 
variant 
V/I 69 ENST00000302823.7 
Exon 2 (+) rs757566658 2:203870682 T/C C=0.00002/2 (ExAC) < 0.01 missense 
variant 
V/A 69 ENST00000302823.7 
Exon 2 (*) rs606231422 2:203870684 C/T NA  missense 
variant 
R/W 70 ENST00000302823.7 
Exon 2 (+) rs781579729 2:203870691 C/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
T/I 72 ENST00000302823.7 
Exon 2 (§) rs199943943 2:203870692 A/G G=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
T 72 ENST00000302823.7 
Exon 2 (§) rs866679318 2:203870695 G/T NA  synonymous 
variant 
V 73 ENST00000302823.7 
Exon 2 (+) rs754725143 2:203870712 G/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
S/I 79 ENST00000302823.7 
Exon 2 (§) rs778678737 2:203870716 G/A A=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
Q 80 ENST00000302823.7 
Exon 2 (§) rs139154557 2:203870722 T/C C=0.00008/1 (GO-ESP) < 0.01 synonymous 
variant 
T 82 ENST00000302823.7 
Exon 2 (+) rs775877536 2:203870729 TG/- -=0.000008/1 (ExAC) < 0.01 frameshift 
variant 
C/X 85 ENST00000302823.7 
Exon 2 (*) rs376038796 2:203870733 C/T T=0.00002/3 (ExAC); 
T=0.0002/1 (1000 
Genomes); 
T=0.00008/1 (GO-ESP); 
T=0.0001/3 (TOPMED) 
< 0.01 missense 
variant 
A/V 86 ENST00000302823.7 
Exon 2 (§) rs771695723 2:203870734 G/A A=0.00004/5 (ExAC) < 0.01 synonymous 
variant 
A 86 ENST00000302823.7 
Exon 2 (+) rs370443546 2:203870744 A/G G=0.000008/1 (ExAC); 
G=0.00008/1 (GO-ESP); 
G=0.00003/1 
< 0.01 missense 
variant 
M/V 90 ENST00000302823.7 
(TOPMED) 
Exon 2 (+) rs746900785 2:203870747 A/T T=0.00002/2 (ExAC) < 0.01 missense 
variant 
M/L 91 ENST00000302823.7 
Exon 2 (+) rs1065442 2:203870748 T/C NA < 0.01 missense 
variant 
M/T 91 ENST00000302823.7 
Exon 2 (+) rs1052219132 2:203870749 G/A NA < 0.01 missense 
variant 
M/I 91 ENST00000302823.7 
Exon 2 (+) rs770666846 2:203870757 A/T  T=0.000008/1 (ExAC) < 0.01 missense 
variant 
E/V 94 ENST00000302823.7 
Exon 2 (+) rs896360225 2:203870780 A/G NA  missense 
variant 
I/V 102 ENST00000302823.7 
Exon 2 (+) rs776440178 2:203870782 C/G  G=0.000008/1 (ExAC) < 0.01 missense 
variant 
I/M 102 ENST00000302823.7 
Exon 2 (+) rs759232662 2:203870787 C/T T=0.00002/2 (ExAC) < 0.01 missense 
variant 
T/M 104 ENST00000302823.7 
Exon 2 (§) rs770065318 2:203870788 G/A A=0.00005/6 (ExAC) < 0.01 synonymous 
variant 
T 104 ENST00000302823.7 
Exon 2 (§) rs949253264 2:203870791 C/T NA < 0.01 synonymous 
variant 
G 105 ENST00000302823.7 
Exon 2 (+) rs777843969 2:203870793 C/T NA  missense 
variant 
T/I 106 ENST00000302823.7 
Exon 2 (*) rs144988077 2:203870802 G/A A=0.0002/29 (ExAC); 
A=0.0002/1 (1000 
Genomes); A=0.0002/2 
(GO-ESP) 
< 0.01 missense 
variant 
G/E 109 ENST00000302823.7 
Exon 2 (+) rs763030646 2:203870808 A/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
Q/L 111 ENST00000302823.7 
Exon 2 (+) rs764089901 2:203870828 G/C C=0.000008/1 (ExAC); 
C=0.00003/1 (TOPMED) 
< 0.01 missense 
variant 
G/R 118 ENST00000302823.7 
Exon 2 (+) rs752037577 2:203870840 A/G G=0.00002/3 (ExAC) < 0.01 missense 
variant 
M/V 122 ENST00000302823.7 
Exon 2 (+) rs757773669 2:203870847 C/T  T=0.000008/1 (ExAC) < 0.01 missense 
variant 
T/M 124 ENST00000302823.7 
Exon 2 (§) rs372929906 2:203870848 G/A A=0.00007/9 (ExAC); 
A=0.0002/2 (GO-ESP); 
A=0.0004/11 
(TOPMED) 
< 0.01 synonymous 
variant 
T 124 ENST00000302823.7 
Exon 2 (§) rs943460449 2:203870854 C/G G=0.00003/1 
(TOPMED) 
< 0.01 synonymous 
variant 
L 126 ENST00000302823.7 
Exon 2 (+) rs750841862 2:203870860 C/G G=0.00002/2 (ExAC) < 0.01 missense 
variant 
I/M 128 ENST00000302823.7 
Exon 2 (§) rs147679342 2:203870866 G/A A=0.00008/1 (GO-ESP) < 0.01 synonymous 
variant 
K 130 ENST00000302823.7 
Exon 2 (§) rs188862082 2:203870887 G/A A=0.00006/7 (ExAC); 
A=0.0002/1 (1000 
Genomes) 
< 0.01 synonymous 
variant 
P 137 ENST00000302823.7 
Exon 2 (§) rs376126248 2:203870890 A/T T=0.00002/2 (ExAC); 
T=0.00008/1 (GO-ESP) 
< 0.01 synonymous 
variant 
P 138 ENST00000302823.7 
Exon 2 (§) rs752339954 2:203870897 C/T T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
L 141 ENST00000302823.7 
Exon 2 (+) rs757989570 2:203870903 A/G G=0.000008/1 (ExAC) < 0.01 missense 
variant 
I/V 143 ENST00000302823.7 
Exon 2 (§) rs777300741 2:203870911 C/T T=0.00003/4 (ExAC); 
T=0.00003/1 (TOPMED) 
< 0.01 synonymous 
variant 
N 145 ENST00000302823.7 
Exon 2 (§) rs746944635 2:203870929 A/C C=0.000009/1 (ExAC) < 0.01 synonymous 
variant 
V 151 ENST00000302823.7 
Exon 3 (+) rs756706504 2:203871387 C/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
P/L 156 ENST00000302823.7 
Exon 3 (§) rs200657280 2:203871388 G/A A=0.00009/11 (ExAC); 
A=0.0002/2 (GO-ESP); 
A=0.0003/9 (TOPMED) 
< 0.01 synonymous 
variant 
P 156 ENST00000302823.7 
Exon 3 (+) rs745734610 2:203871393 C/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
P/L 158 ENST00000302823.7 
Exon 3 (+) rs778733155 2:203871399 C/G NA  missense 
variant 
S/C 160 ENST00000302823.7 
Exon 3 (§) rs1018212735 2:203871406 C/T NA  synonymous F 162 ENST00000302823.7 
variant 
Exon 3 (§) rs755931042 2:203871409 C/T  T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
L 163 ENST00000302823.7 
Exon 3 (+) rs779775271 2:203871416 A/G G=0.000008/1 (ExAC) < 0.01 missense 
variant 
I/V 166 ENST00000302823.7 
Exon 3 (§) rs749059847 2:203871421 T/C C=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
L 167 ENST00000302823.7 
Exon 3 (+) rs768961499 2:203871432 G/C C=0.000008/1 (ExAC) < 0.01 missense 
variant 
S/T 171 ENST00000302823.7 
Exon 3 (+) rs963824682 2:203871435 C/T T=0.00007/2 (TOPMED) < 0.01 missense 
variant 
S/L 172 ENST00000302823.7 
Exon 3 (§) rs375949600 2:203871436 G/A A=0.00007/9 (ExAC); 
A=0.0002/2 (GO-ESP); 
A=0.0005/16 
(TOPMED) 
< 0.01 synonymous 
variant 
S 172 ENST00000302823.7 
Exon 3 (§) rs146571801 2:203871466 A/T T=0.000008/1 (ExAC); 
T=0.00008/1 (GO-ESP); 
T=0.00003/1 (TOPMED) 
< 0.01 synonymous 
variant 
T 182 ENST00000302823.7 
Exon 3 (+) rs771987351 2:203871467 G/T T=0.000008/1 (ExAC) < 0.01 missense 
variant 
A/S 183 ENST00000302823.7 
Exon 3 (§) rs199659316 2:203871469 T/C NA  synonymous 
variant 
A 183 ENST00000302823.7 
Exon 3 (+) rs773775010 2:203871473 T/A A=0.00002/3 (ExAC) < 0.01 missense 
variant 
S/T 185 ENST00000302823.7 
Exon 3 (+) rs761227535 2:203871477 T/C C=0.00002/2 (ExAC) < 0.01 missense 
variant 
L/S 186 ENST00000302823.7 
Exon 3 (+) rs766875859 2:203871483 A/G G=0.00003/4 (ExAC) < 0.01 missense 
variant 
K/R 188 ENST00000302823.7 
Exon 3 (+) rs199912925 2:203871485 A/G G=0.00003/4 (ExAC) < 0.01 missense 
variant~splice 
region variant 
M/V 189 ENST00000302823.7 
Exon 3 (*) rs606231419 2:203871492 G/C NA  splice region 
variant~intron 
  ENST00000302823.7 
variant 
Exon 4 (§) rs1037900731 2:203872713 G/A A=0.00003/1 
(TOPMED) 
< 0.01 synonymous 
variant 
K 191 ENST00000302823.7 
Exon 4 (+) rs745310078 2:203872722 C/A NA  missense 
variant 
S/R 194 ENST00000302823.7 
Exon 4 (+) rs767174634 2:203872733 C/A A=0.000008/1 (ExAC) < 0.01 missense 
variant 
T/K 198 ENST00000302823.7 
Exon 4 (§) rs749973402 2:203872737 G/T T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
G 199 ENST00000302823.7 
Exon 4 (+) rs1046533169 2:203872738 G/T NA  missense 
variant 
V/F 200 ENST00000302823.7 
Exon 4 (+) rs755615887 2:203872739 T/C C=0.000008/1 (ExAC) < 0.01 missense 
variant 
V/A 200 ENST00000302823.7 
Exon 4 (§) rs74808460 2:203872755 C/G G=0.00004/5 (ExAC); 
G=0.0002/1 (1000 
Genomes) 
< 0.01 synonymous 
variant 
P 205 ENST00000302823.7 
Exon 4 (§) rs753717111 2:203872761 A/G G=0.000008/1 (ExAC)  synonymous 
variant 
T 207 ENST00000302823.7 
Exon 4 (§) rs754809262 2:203872764 G/A A=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
E 208 ENST00000302823.7 
Exon 4 (+) rs778534474 2:203872766 C/G G=0.000008/1 (ExAC) < 0.01 missense 
variant 
P/R 209 ENST00000302823.7 
Exon 4 (+) rs527697475 2:203872771 T/C C=0.0002/1 (1000 
Genomes) 
< 0.01 missense 
variant 
C/R 211 ENST00000302823.7 
Exon 4 (§) rs752988825 2:203872776 A/G G=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
E 212 ENST00000302823.7 
Exon 4 (+) rs758600786 2:203872786 C/T T=0.000008/1 (ExAC) < 0.01 stop gained Q/* 216 ENST00000302823.7 
Exon 4 (§) rs778114608 2:203872794 T/C C=0.00002/2 (ExAC) < 0.01 synonymous 
variant 
Y   218 ENST00000302823.7 
Exon 4 (§) rs747155841 2:203872803 C/T T=0.000008/1 (ExAC) < 0.01 synonymous 
variant 
P 221 ENST00000302823.7 
Exon 4 (+) rs367760388 2:203872804 A/G NA  missense 
variant 
I/V 222 ENST00000302823.7 
Exon 4 (§) rs370517673  2:203872806 C/T NA  synonymous 
variant 
I 222 ENST00000302823.7 
“*” indicates variants which have previously been published as disease causing or are part of our cohort. “§” indicates variants which have no disease causing effect in mutation 
carriers. “+” indicates variants whose effect on disease manifestation has to be explored. This data was extracted from Ensembl. 
 
